These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 25272669)

  • 1. [Treatment of dyslipidemia in 2014: European versus American guidelines].
    Radermecker RP
    Rev Med Suisse; 2014 Aug; 10(439):1534-7. PubMed ID: 25272669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New European and American guidelines on the management of blood cholesterol : similarities and differences].
    Butty A; Rodondi N; Nanchen D
    Rev Med Suisse; 2020 Mar; 16(684):438-443. PubMed ID: 32134222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.
    Bongard V; Dallongeville J; Arveiler D; Ruidavets JB; Amouyel P; Wagner A; Ferrières J
    Arch Cardiovasc Dis; 2013 Feb; 106(2):93-102. PubMed ID: 23527913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new dyslipidemia guidelines: what is the debate?
    Anderson TJ; Mancini GB; Genest J; Grégoire J; Lonn EM; Hegele RA
    Can J Cardiol; 2015 May; 31(5):605-12. PubMed ID: 25816728
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guidelines in the USA, a viewpoint contrary to those guidelines in Europe, Canada, Britain and the International Atherosclerosis Society.
    Saraf S; Ray KK
    Curr Opin Lipidol; 2014 Dec; 25(6):413-7. PubMed ID: 25268983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic.
    Barkas F; Liberopoulos EN; Kostapanos MS; Liamis G; Tziallas D; Elisaf M
    Angiology; 2015 Apr; 66(4):346-53. PubMed ID: 24830420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Are therapeutic LDL goals justified? Controversies between the European and American guidelines].
    Bertomeu-Martínez V
    Medwave; 2016 Dec; 16(Suppl4):e6825. PubMed ID: 28055995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Multimodal therapy of dyslipidemia].
    Stahn A; Hanefeld M
    Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The discussion on target goals in lipid reduction is still going on. The Expert Committee--a block for current cardiovascular prevention].
    Olsson AG
    Lakartidningen; 2011 Nov 23-29; 108(47):2442-3. PubMed ID: 22468387
    [No Abstract]   [Full Text] [Related]  

  • 10. Simplifying the approach to the management of dyslipidemia.
    Gaziano JM; Gaziano TA
    JAMA; 2009 Nov; 302(19):2148-9. PubMed ID: 19920241
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of therapeutic lipid target achievements among high-risk patients in Oman.
    Al-Waili K; Al-Zakwani I; Al-Dughaishi T; Baneerje Y; Al-Sabti H; Al-Hashmi K; Farhan H; Habsi KA; Al-Hinai AT; Al-Rasadi K
    Angiology; 2014 May; 65(5):430-5. PubMed ID: 23564019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Lipid management--treatment goal and strategy].
    Koshiyama H
    Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What's next for dyslipidemia management? The 2013 ACC/AHA Guidelines, the NLA recommendations, and beyond.
    Waite LH; Phan YL; Spinler SA
    J Am Pharm Assoc (2003); 2016; 56(3):284-92. PubMed ID: 27156942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reasons for a combination].
    Núñez-Cortés JM
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():40-1. PubMed ID: 25043547
    [No Abstract]   [Full Text] [Related]  

  • 17. Residual dyslipidaemia after statin treatment in France: Prevalence and risk distribution.
    Ferrières J; Bérard E; Crisan O; Bongard V
    Arch Cardiovasc Dis; 2010 May; 103(5):302-9. PubMed ID: 20619240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of dyslipidemia and cardiovascular outcomes: the journey so far--is this the end for statins?
    Zoungas S; Curtis AJ; McNeil JJ; Tonkin AM
    Clin Pharmacol Ther; 2014 Aug; 96(2):192-205. PubMed ID: 24727468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of low-density lipoprotein targets.
    Whayne TF
    Angiology; 2013 Aug; 64(6):411-6. PubMed ID: 22734087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Spanish Interdisciplinary Committee for Cardiovascular Disease Prevention and the Spanish Society of Cardiology position statement on dyslipidemia management. Differences between the European and American guidelines].
    Lobos Bejarano JM; Galve E; Royo-Bordonada MÁ; Alegría Ezquerra E; Armario P; Brotons Cuixart C; Camafort Babkowski M; Cordero Fort A; Maiques Galán A; Mantilla Morató T; Pérez Pérez A; Pedro-Botet J; Villar Álvarez F; González-Juanatey JR;
    Clin Investig Arterioscler; 2015; 27(1):36-44. PubMed ID: 25444651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.